Evidence map›Paper›PMID 39158822›Full record

ReviewTransgenic research2024

Next-generation CRISPR technology for genome, epigenome and mitochondrial editing.

Cia-Hin Lau, Qing-Le Liang, Haibao Zhu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Transgenic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Epigenetic editing: from concept to clinic.Nature reviews. Drug discovery · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cia-Hin LauDepartment of Biology, College of Science, Shantou University, Shantou, 515063, Guangdong, China.ORCID 0000-0002-4528-0363
Qing-Le LiangDepartment of Clinical Laboratory Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.ORCID 0009-0008-5975-2078
Haibao ZhuDepartment of Biology, College of Science, Shantou University, Shantou, 515063, Guangdong, China. zhuhaibao@stu.edu.cn.ORCID 0009-0005-1982-678X

Funding

Guangdong Provincial Natural Science Foundation General Project 2023A1515011906Shantou University Research Initiation Fund Project NTF20030Xiamen Municipal Bureau of Science and Technology-National Foreign Expert Program QN2023021001L
6 · The paper itself

Abstract

The application of rapidly growing CRISPR toolboxes and methods has great potential to transform biomedical research. Here, we provide a snapshot of up-to-date CRISPR toolboxes, then critically discuss the promises and hurdles associated with CRISPR-based nuclear genome editing, epigenome editing, and mitochondrial editing. The technical challenges and key solutions to realize epigenome editing in vivo, in vivo base editing and prime editing, mitochondrial editing in complex tissues and animals, and CRISPR-associated transposases and integrases in targeted genomic integration of very large DNA payloads are discussed. Lastly, we discuss the latest situation of the CRISPR/Cas9 clinical trials and provide perspectives on CRISPR-based gene therapy. Apart from technical shortcomings, ethical and societal considerations for CRISPR applications in human therapeutics and research are extensively highlighted.

Indexed as

CRISPR-Cas SystemsEpigenomeGene EditingMitochondriaAnimalsClustered Regularly Interspaced Short Palindromic RepeatsGenetic TherapyGenomeHumansBase editorCRISPREpigenome editingGenome editingIntegraseMitochondrial editingPrime editorTransposase

Identifiers

PMID39158822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.